FRET-Based Actin Binding Assay for Real-Time Modulator Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the capability to effectively monitor and modulate the intermolecular interactions between actin-binding proteins and actin filaments in real-time, particularly for mutant proteins associated with human diseases, which are linked to increased binding affinity, leading to unaddressed diseases with no cures or treatments.
Innovation Solution
A FRET-based assay using genetically engineered cells expressing actin-binding proteins with fluorescent probes, such as GFP-ABD-L253P and Lifeact-mCherry, allows for real-time monitoring of interactions with actin filaments and identification of compounds that alter these interactions, enabling the detection of changes in binding affinity and potential therapeutic compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional binding assays are used to monitor actin-binding protein interactions, then the method is simple to perform, but real-time monitoring capability is lost and measurement precision is insufficient
Solution Approach 1:
The patent introduces FRET pairs (donor and acceptor fluorophores) as intermediary elements that mediate the detection of protein-protein interactions. The donor fluorophore is attached to one actin-binding protein while the acceptor is attached to another, allowing indirect monitoring of their binding events through energy transfer signals, thereby achieving real-time measurement without directly observing the proteins themselves.
Solution Approach 2:
The patent replaces traditional mechanical or chemical binding assays with an optical detection system based on fluorescence resonance energy transfer. Instead of using physical separation or chemical indicators to detect binding, the system uses non-radiative energy transfer between fluorophores to report on molecular interactions in real-time.
2Reliability
If mutant actin-binding proteins with increased binding affinity are studied, then disease mechanisms can be understood, but the ability to identify therapeutic compounds is hindered due to no existing treatments
Solution Approach 1:
The patent implements a feedback-based screening system where the FRET signal provides real-time information about compound effects on mutant protein binding. By monitoring changes in energy transfer efficiency upon compound addition, the system automatically identifies compounds that modulate the aberrant binding interactions, creating a closed-loop approach to drug discovery that adapts to the specific disease-causing mutations.
3Productivity
If high-throughput screening is implemented to identify therapeutic compounds, then productivity increases, but the complexity of the screening system and data analysis increases
Solution Approach 1:
The patent creates a universal FRET-based assay platform that can screen multiple different mutant actin-binding proteins using the same basic methodology. The system is designed to accommodate various donor-acceptor fluorophore pairs and can be applied to different disease-associated mutations, allowing high-throughput screening across multiple targets without requiring separate specialized assays for each protein or mutation type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay provides a high-throughput screening method to identify compounds that reduce aberrant actin-binding affinity of mutant proteins, potentially leading to therapeutic interventions for diseases like spinocerebellar ataxia type 5 and other actin-linked cytoskeletal disorders.
Implementation Method 1
A FRET-based assay using genetically engineered cells expressing actin-binding proteins with fluorescent probes, such as GFP-ABD-L253P and Lifeact-mCherry, allows for real-time monitoring of interactions with actin filaments
Data Source
AI summary
The present disclosure provides methods for identifying compounds that cause structural changes in a protein bound to an actin filament. The methods include the use of cells that include two actin-binding proteins, each labeled with a chromophore, and exposing the cells to a test compound. The method further includes detecting a change in fluorescence resonance energy transfer (FRET) between the chromophores.